Globus Medical director Tobin sells 37,662-share block
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Globus Medical Inc. (GMED) director James R. Tobin exercised options for 15,000 Class A shares at an exercise price of $65.05 per share, 21,458 at $53.27, and 5,208 at $43.58 on November 10, 2026. He sold 37,662 shares at a weighted average price of $75.1025 per share, with reported sale prices ranging from $74.58 to $75.53, and another 4,004 shares at a weighted average price of $75.6836, with reported sale prices from $75.60 to $76.05. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy Class A Common Stock) F3 | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy Class A Common Stock) F4 | 21,458 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy Class A Common Stock) F5 | 5,208 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 15,000 | $65.05 | $976K |
| Exercise | Class A Common Stock | 21,458 | $53.27 | $1.14M |
| Exercise | Class A Common Stock | 5,208 | $43.58 | $227K |
| Sale | Class A Common Stock F1 | 37,662 | $75.1025 | $2.83M |
| Sale | Class A Common Stock F2 | 4,004 | $75.6836 | $303K |
Footnotes (5)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.58 to $75.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.60 to $76.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3. These options were granted on January 14, 2021 and are fully vested.
- F4. These options were granted on January 22, 2020 and are fully vested.
- F5. These options were granted on January 22, 2019 and are fully vested.
Key Figures
Key Terms
weighted average price financial
fully vested financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.